Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib Roll-over Study in ALK Positive Malignancies
NCT02584933Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2015
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 4 trial of ceritinib in malignant neoplasm, sponsored by Novartis. Started Dec 2015; status: active, not recruiting.
02
Drugs
ceritinib
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT02584933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02584933.